In addition, high MICALL2 expression was associated with poor overall survival of patients with grade 3–4 ovarian cancer (Figure 1F,G) and poor progression-free survival of patients with stage T3–T4 ovarian cancer (Figure 1H,I). Here, MICALL2 is linked to ovarian carcinoma.